MAINTENANCE OLAPARIB RECHALLENGE IN PATIENTS WITH OVARIAN CANCER PREVIOUSLY TREATED WITH A PARP INHIBITOR: PATIENTREPORTED OUTCOMES FROM THE PHASE IIIB OREO/ENGOT-OV38 TRIAL

被引：0

作者：

Redondo, Andres ^{[1
,2
]}

Follana, Philippe ^{[3
,4
]}

Scambia, Giovanni ^{[5
,6
]}

Asselain, Bernard ^{[7
]}

Marme, Frederik ^{[8
,9
]}

Mirza, Mansoor ^{[10
,11
]}

Laudani, Maria Elena ^{[12
]}

Madry, Radoslaw ^{[13
,14
]}

Glasspool, Rosalind ^{[15
,16
,17
]}

You, Benoit ^{[18
,19
]}

Jesus Rubio-Perez, Maria ^{[20
,21
]}

Zamagni, Claudio ^{[22
,23
]}

El-Balat, Ahmed ^{[24
,25
]}

Hardy-Bessard, Anne Claire ^{[26
,27
]}

Oaknin, Ana ^{[28
,29
]}

Ronzino, Graziana ^{[30
,31
]}

Shaw, Bob ^{[32
]}

Nakamura, Hitomi ^{[33
]}

Berton, Dominique ^{[34
]}

Pujade-Lauraine, Eric ^{[35
]}

机构：

[1] La Paz Univ Hosp, Madrid, Spain

[2] GEICO, Dept Med, Madrid, Spain

[3] Ctr Antoine Lacassagne, Nice, France

[4] GINECO, Dept Med Oncol, Nice, France

[5] Fdn Policlin Univ A Gemelli, IRCCS, UOC Ginecol Oncol, Rome, Italy

[6] MITO, Dipartimento Salute Donna & Bambino & Salute Pubb, Rome, Italy

[7] ARCAGY GINECO, Dept Biostat, Paris, France

[8] Heidelberg Univ, Univ Hosp Mannheim, Mannheim, Germany

[9] AGO, Med Fac Mannheim, Mannheim, Germany

[10] Rigshosp, Copenhagen, Denmark

[11] NSGO, Dept Canc Treatment, Copenhagen, Denmark

[12] Univ Turin, St Anna Hosp, Dept Gynecol & Obstet, Turin, Italy

[13] Poznan Univ Med Sci, Poznan, Poland

[14] PGOG, Dept Gynecol Oncol, Poznan, Poland

[15] Univ Glasgow, Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland

[16] Univ Glasgow, Inst Canc Sci, Glasgow, Lanark, Scotland

[17] NCRI, Med Oncol, Glasgow, Lanark, Scotland

[18] HCL Ctr Hosp Lyon Sud, Lyon, France

[19] GINECO, Dept Med Oncol, Lyon, France

[20] Reina Sofia Univ Hosp, Cordoba, Spain

[21] GEICO, Dept Med Oncol, Cordoba, Spain

[22] IRCCS Azienda Osped Univ Bologna, Bologna, Italy

[23] MITO, Med Oncol Unit, Bologna, Italy

[24] Klinikum Johann Wolfgang Goethe Univ, Frankfurt, Germany

[25] AGO, Dept Gynecol & Gynecol Oncol, Frankfurt, Germany

[26] Ctr CARIO HPCA, Plerin, France

[27] GINECO, Med Oncol, Plerin, France

[28] Hosp Univ Vall dHebron, Vall dHebron Inst Oncol VHIO, Vall dHebron Barcelona Hosp Campus, Barcelona, Spain

[29] GEICO, Gynaecol Canc Programme, Barcelona, Spain

[30] Vito Fazzi Hosp, Lecce, Italy

[31] MITO, Med Oncol Unit, Lecce, Italy

[32] AstraZeneca, Stat, Cambridge, England

[33] AstraZeneca, Global Med Affairs, Cambridge, England

[34] Inst Cancerol Ouest, Med Oncol, St Herblain, France

[35] ARCAGY GINECO, Dept Med Oncol, Paris, France

来源：

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2022年 / 32卷

关键词：

D O I：

10.1136/ijgc-2022-igcs.27

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

O025/#522

引用

页码：A15 / A15

页数：1

共 50 条

[41] THE ENGOT-OV26/PRIMA PHASE 3 TRIAL: NIRAPARIB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER WHO RESPONDED TO FRONT-LINE PLATINUM-BASED THERAPY
Gonzalez Martin, A.
Rojas, L. A.
Braly, P.
Barter, J.
O'Malley, D. M.
Oza, A.
Haggerty, A.
Vulsteke, C.
Provencher, D.
Graybill, W.
Li, Y.
Malinowska, I. A.
Mirza, M. R.
Vergote, I.
Pothuri, B.
Monk, B. J.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1510 - 1510
[42] A single-arm, phase II study of niraparib and bevacizumab maintenance in patients with platinum-sensitive, recurrent ovarian cancer previously treated with a PARP inhibitor (KGOG 3056/NIRVANA-R)
Cho, Hyun-Woong
Park, Jeong-Yeol
Kim, Byoung Gie
Kim, Jae-Weon
Lim, Myong Cheol
Choi, Min Chul
Jeong, Dae Hoon
Lee, Jung-Yun
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (SUPPL_4) : A61 - A62
[43] A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45)
Monk, Bradley J.
Parkinson, Christine
Lim, Myong Cheol
O'Malley, David M.
Oaknin, Ana
Wilson, Michelle K.
Coleman, Robert L.
Lorusso, Domenica
Bessette, Paul
Ghamande, Sharad
Christopoulou, Athina
Provencher, Diane
Prendergast, Emily
Demirkiran, Fuat
Mikheeva, Olga
Yeku, Oladapo
Chudecka-Glaz, Anita
Schenker, Michael
Littell, Ramey D.
Safra, Tamar
Chou, Hung-Hsueh
Morgan, Mark A.
Drochytek, Vit
Barlin, Joyce N.
Van Gorp, Toon
Ueland, Fred
Lindahl, Gabriel
Anderson, Charles
Collins, Dearbhaile C.
Moore, Kathleen
Marme, Frederik
Westin, Shannon N.
McNeish, Iain A.
Shih, Danny
Lin, Kevin K.
Goble, Sandra
Hume, Stephanie
Fujiwara, Keiichi
Kristeleit, Rebecca S.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (34) : 3952 - 3964
[44] Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis
Labidi-Galy, S. I.
Rodrigues, M.
Sandoval, J. L.
Kurtz, J. E.
Heitz, F.
Mosconi, A. M.
Romero, I.
Denison, U.
Nagao, S.
Vergote, I.
Parma, G.
Nottrup, T. J.
Rouleau, E.
Garnier, G.
El-Balat, A.
Zamagni, C.
Martin-Lorente, C.
Pujade-Lauraine, E.
Fievet, A.
Ray-Coquard, I. L.
ANNALS OF ONCOLOGY, 2023, 34 (02) : 152 - 162
[45] Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
Pujade-Lauraine, Eric
Ledermann, Jonathan A.
Selle, Frederic
Gebski, Val
Penson, Richard T.
Oza, Amit M.
Korach, Jacob
Huzarski, Tomasz
Poveda, Andres
Pignata, Sandro
Friedlander, Michael
Colombo, Nicoletta
Harter, Philipp
Fujiwara, Keiichi
Ray-Coquard, Isabelle
Banerjee, Susana
Liu, Joyce
Lowe, Elizabeth S.
Bloomfield, Ralph
Pautier, Patricia
LANCET ONCOLOGY, 2017, 18 (09): : 1274 - 1284
[46] ENGOT-ov43/keylynk-001: A phase III, placebo- and active-controlled trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of advanced BRCA-nonmutated epithelial ovarian cancer
Coleman, R. L.
Fujiwara, K.
Sehouli, J.
Salutari, V.
Zola, P.
Madry, R.
Korach, J.
Pautier, P.
Cibula, D.
Lheureux, S.
Hasegawa, K.
Kim, B. G.
Lai, C. H.
Gonzalez-Martinez, A.
Liu, Q.
Keefe, S.
Puglisi, M.
Topuz, S.
Monk, B. J.
Arend, R. C.
O'Malley, D. M.
Vergote, I.
GYNECOLOGIC ONCOLOGY, 2020, 159 : 89 - 90
[47] A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial
Park, Junsik
Lim, Myong Cheol
Lee, Jae-Kwan
Jeong, Dae Hoon
Kim, Se Ik
Choi, Min Chul
Kim, Byoung-Gie
Lee, Jung-Yun
JOURNAL OF GYNECOLOGIC ONCOLOGY, 2022, 33 (02)
[48] Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
Ledermann, Jonathan
Harter, Philipp
Gourley, Charlie
Friedlander, Michael
Vergote, Ignace
Rustin, Gordon
Scott, Clare L.
Meier, Werner
Shapira-Frommer, Ronnie
Safra, Tamar
Matei, Daniela
Fielding, Anitra
Spencer, Stuart
Dougherty, Brian
Orr, Maria
Hodgson, Darren
Barrett, J. Carl
Matulonis, Ursula
LANCET ONCOLOGY, 2014, 15 (08): : 852 - 861
[49] Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial
Frenel, J. S.
Kim, J. W.
Aryal, N.
Asher, R.
Berton, D.
Vidal, L.
Pautier, P.
Ledermann, J. A.
Penson, R. T.
Oza, A. M.
Korach, J.
Huzarski, T.
Pignata, S.
Colombo, N.
Park-Simon, T. W.
Tamura, K.
Sonke, G. S.
Freimund, A. E.
Lee, C. K.
Pujade-Lauraine, E.
ANNALS OF ONCOLOGY, 2022, 33 (10) : 1021 - 1028
[50] Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial
Friedlander, Michael
Gebski, Val
Gibbs, Emma
Davies, Lucy
Bloomfield, Ralph
Hilpert, Felix
Wenzel, Lari B.
Eek, Daniel
Rodrigues, Manuel
Clamp, Andrew
Penson, Richard T.
Provencher, Diane
Korach, Jacob
Huzarski, Tomasz
Vidal, Laura
Salutari, Vanda
Scott, Clare
Nicoletto, Maria Ornella
Tamura, Kenji
Espinoza, David
Joly, Florence
Pujade-Lauraine, Eric
LANCET ONCOLOGY, 2018, 19 (08): : 1126 - 1134

← 1 2 3 4 5 →